Othman Laraki
Co-founder and CEO @ Color
San Francisco, United States
Othman Laraki is a seed investor at Color in San Francisco focused on Software and Internet. Othman Laraki, MS, MBA, is the Co-founder and Chief Executive Officer of Color, a health technology company building public health infrastructures such as scaled and efficient testing to contain the COVID-19 pandemic or using genomics for population health. Previously, Othman co-founded Mixer Labs and developed its GeoAPI platform, a powerfullocation engine for developers. After the company was acquired by Twitter in 2009, he served as the social media network’s Vice President of Product and helped expand its user base from 50 to 200 million unique accounts. Before this, Othman spent several years at Google, where he played an integral role developing front-end products, including the Chrome browser.Othman is a long-time investor and advisor to leading companies such as Pinterest, AngelList, Slack and Instacart, and serves as a board member for ESI Group and Frontier Medicines. He holds degrees in computer science and management from Stanford University and the Massachusetts Institute of Technology.
- Total investments:
- 43
- Last investment:
- Lead investor:
- 2%
Last updated:
For AI agents: llms.txt
Industries Othman Laraki invests in
Stages Othman Laraki invests in
Countries Othman Laraki invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $775k–$14M
- Angel
- $975k–$1.5M
- Series A
- $1.5M–$29M
Investment Focus
Industry
- Software 11 (26%)
- Internet 9 (21%)
- Health Care 8 (19%)
- Information Technology 7 (16%)
- SaaS 6 (14%)
Stage
- Seed 27 (63%)
- Series A 5 (12%)
- Angel 3 (7%)
- Pre-Seed 3 (7%)
- Funding Round 3 (7%)
Country
- United States 37 (86%)
- India 1 (2%)
- Sweden 1 (2%)
- The Netherlands 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Uncovr
|
Uncovr is an AI-powered surgical intelligence and documentation platform that automatically transforms operating room videos into structured clinical reports and billing codes. | $7M / Seed / Jun 10, 2026 | |
SRE.ai
|
SRE.ai delivers AI agents that automate Salesforce DevOps workflows, allowing for fast, transparent deployments, back-promotions, and impact analysis. With seamless tool integration, SRE.ai minimizes clicks and maximizes productivity, enabling teams to scale without sacrificing quality or speed. | $7.2M / Seed / Aug 20, 2025 | |
Bluenote Health
|
Bluenote Health operates as an AI platform for life sciences. | $10M / Dec 20, 2024 | |
Yupp
|
Yupp a discovering, contrasting, and utilizing the newest AIs is made simple and enjoyable, which also contributes to the field's future development.. | $33M / Seed / Jun 01, 2024 | |
YardStream
|
YardStream is a Metaverse company & an all-in-one virtual and hybrid event platform for virtual events, summits, meetups, workshops and in-person events for communities & enterprises. Specializing in augmented reality solutions, spatial mapping and 3D models. Each Business Delivers a Disruptive End-to-End Solution Backed by AI, 3D, AR, andML. | $500K / Pre-Seed / Dec 15, 2023 | |
Exponential DeFi
|
Exponential DeFi platform makes it easy to discover, assess, and invest in DeFi yield opportunities. | $14M / Seed / Oct 03, 2022 | |
Evernow
|
Evernow is a provider of women's health care services before, during, and after menopause. Their platform has online access to specialized doctors, science-backed information, and treatments, along with conversations and information about effective care for changing hormones, enabling women to live longer and healthier lives. | $28.5M / Series A / Apr 06, 2022 | |
Detail
|
Detail Technologies is a virtual camera that you can use in Zoom, Loom, Meet, Whereby, or your favorite streaming software. | $2M / Pre-Seed / Mar 09, 2021 | |
Earli
|
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | $19.5M / Seed / Sep 17, 2018 | |
OMNY Health
|
Revolutionizing how healthcare data is shared and valued. | Feb 01, 2018 | |
| See all 43 investments → | |||
Co-Investors
About Color
Color is a population health technology company that focuses on providing large-scale health care programs and clinical testing. It improves the key health infrastructure systems to make health accessible, convenient, and cost-effective, serving health systems, employers, research institutions, and individual consumers.Its Population GenomicsPlatform offers modular and end-to-end solutions that enable organizations to effectively build and scale population health programs. It provides technology, software, and clinical services to help population programs launch and scale quickly. By combining innovative technology, specialized laboratory infrastructure, and clinical health services, Color creates complete and effective programs that include: Program strategy, planning, and implementation; Participant outreach and engagement; participant education and consent about testing and results; sample (blood or saliva) collection and genetic sequencing; data management and clinical reporting; HIPAA compliance and data security; return of results; clinical services, like genetic counseling and clinical pharmacy; personalized care routine; and ongoing population health management. Color’s partners include NorthShore University Health System, the National Institutes of Health (NIH), Ochsner Health System, Verily, Visa, Levi Strauss, and Salesforce.Elad Gil, Nish Bhat, Taylor Sittler, and Othman Laraki launched Color in 2015 and is based in Burlingame, California.
Color Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Claire Vo
Chief Product Officer
|
|||
Elad Gil
Co-founder
|
|||
Alicia Zhou
VP of Research and Scientific Affairs
|
|||
Caroline Savello
VP of Commercial
|
|||
Dror Berman
Investor (Seed round and on)
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Othman Laraki invest in?
Othman Laraki invests primarily in Software, Internet and Health Care startups, most often at Seed and Series A stage. Most of the 43 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Othman Laraki's check size?
Othman Laraki typically joins rounds of $775k–$14M at Seed, $975k–$1.5M at Angel and $1.5M–$29M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Othman Laraki participates in.
How do I contact Othman Laraki?
Public channels for Othman Laraki include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Othman Laraki last invest?
The most recent investment recorded for Othman Laraki closed in Jun 2026. Shizune tracks 43 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
